Biomarkers in Lewy Body Dementia
The goal of this longitudinal study is to discover better biomarkers, measures of what's happening inside the living body, for diagnosis and treatment of Lewy body dementia.
|Minimum Age||Maximum Age||Gender||Healthy Volunteers|
- Diagnosed with dementia with Lewy bodies or with Parkinson's disease with cognitive change
- Speak English or Spanish
- None given
Participants will complete 4 to 5 visits over 3.5 years, including neurological evaluations and collection of blood, urine, and cerebrospinal fluid samples. Researchers will use this information, along with previously collected brain samples, to better understand how the contribution of co-existing Alzheimers disease may affect the diagnosis and clinical course of Lewy body disorders and to develop biomarkers specific to Lewy body dementia.
Columbia University Medical Center
||New York||New York||10032||Recruiting||
The U.S. National Institutes of Health
|Karen Marder, MD||Principal Investigator||Columbia University|
|Lawrence Honig, MD, PhD||Principal Investigator||Columbia University|
|Martha Orbe-Reilly, MDemail@example.com|